Trogenix, a pioneering biotech company based in Edinburgh, UK, has successfully closed a Series A financing round, raising £70 million / $95 million to advance its pipeline of potentially curative cancer therapies. The funding, which represents Cancer Research Horizons’ largest investment to-date into a company, will be used to rapidly accelerate Trogenix's lead program in glioblastoma (GBM) towards first patient dosing anticipated in Q1 2026, as well as a follow-on program for colorectal cancer liver metastases (CRCLM), and further development of its pipeline in liver and lung cancers. This significant investment validates the transformative potential of the company's Odysseusplatform, which is designed to deliver precision genetic medicines with curative "one-and-done" potential across multiple aggressive, treatment-resistant solid tumors.

The Series A round was led by IQ Capital, with participation from founding investor 4BIO Capital and returning investors Cancer Research Horizons and the National Brain Tumor Society’s Brain Tumor Investment Fund. New investors included Eli Lilly and Company, Meltwind, LongeVC, and Calculus Capital, alongside undisclosed private investors. Trogenix's technology uses a "Trojan Horse" approach, employing proprietary Synthetic Super Enhancers (SSEs) that are delivered via AAV vectors to specifically target the unique identity of diseased cells. These SSEs activate a dual payload—a cytotoxic enzyme and an immune-stimulating cytokine—which both kills cancer cells and reawakens the immune system to provide long-term protection against recurrence, leaving surrounding healthy tissue untouched. This revolutionary mechanism is poised to change the treatment paradigm for hard-to-treat cancers like GBM, an aggressive brain cancer with severely limited treatment options. Trogenix's CEO, Ken Macnamara, expressed honor and excitement for the support, which shares the company's mission to deliver breakthrough treatments and pursue cures for patients facing devastating diagnoses.